Tofacitinib dosing is indication- and formulation-specific. The following summary reflects the current U.S. XELJANZ/XELJANZ XR label revised in June 2026 and is not an individualized prescription.
| Treatment setting | Current U.S. labeled regimen |
|---|---|
| Adult RA | XELJANZ 5 mg twice daily or XR 11 mg once daily |
| Adult PsA | XELJANZ 5 mg twice daily or XR 11 mg once daily |
| Adult AS | XELJANZ 5 mg twice daily or XR 11 mg once daily |
| Adult UC induction | XELJANZ 10 mg twice daily or XR 22 mg once daily for 8 weeks; selected patients may continue up to 16 weeks |
| Adult UC maintenance | XELJANZ 5 mg twice daily or XR 11 mg once daily |
| Pediatric PsA / pcJIA ≥40 kg | XELJANZ 5 mg twice daily |
| Pediatric PsA / pcJIA <40 kg | Weight-based twice-daily regimen |
Renal impairment
Dose modification is required for patients with moderate or severe renal impairment. The appropriate regimen depends on the indication and formulation. The full prescribing information should be consulted rather than applying a single dose adjustment to every patient.
Hepatic impairment
The current U.S. label does not recommend XELJANZ/XELJANZ XR in severe hepatic impairment. Dose adjustments are also required in specified moderate hepatic impairment.
Drug-interaction-related modifications
Concomitant CYP2C19 and/or CYP3A4 inhibitors can affect dosing. The prescribing information contains indication-specific modification tables.
Blood-count abnormalities
Dose interruption or other modification may be required for significant lymphopenia, neutropenia or anemia.
Important distinction
A Tofacent 5 mg product must not automatically be assigned the dosing instructions of XELJANZ without verifying its formulation and approved labeling.